Emyria has entered into a crucial license agreement with the University of Western Australia, securing exclusive global rights to a range of patented selective serotonin-releasing agents. These agents, particularly lead compounds MX-100 and MX-200, are targeting mental health and select neurological conditions like PTSD and Parkinson's disease. This partnership is supported by a substantial $499,411 WA government grant and the leads are undergoing advanced screening with key results expected in early 2025. Emyria's commitment to improving treatment outcomes for patients aligns with the development of new treatments as well as care delivery. Compounds that induce serotonin release without releasing dopamine or noradrenaline have the potential to minimise side effects and improve their suitability for clinical applications like assisted psychotherapy and other neurological conditions. If you have any questions or seek further information regarding this exciting development or our approach to mental health treatment, please do not hesitate to reach out. We are enthusiastic about the potential of this compound library and look forward to further progress in our drug development initiatives.